Vicarious Surgical shares surge 18.77% intraday after successfully completing in vivo pig trials for abdominal hernia repair, advancing robot system development toward 2026 design freeze.

Vicarious Surgical surged 18.77% intraday, driven by the announcement of a successful in vivo pig experiment in December 2025. The company reported that surgeons independently used its pre-developed system to complete key elements of an abdominal hernia repair, marking a critical milestone in robotic system development and advancing progress toward a design freeze by year-end 2026.